Congress Opening & Welcome
Alessandro Isidori, MD, PhD, Italy Congress Chair
Session 1: Biology of Leukemias: What's New?
Targeting Leukemia Stem Cells in Myeloid Malignancies: a Tale of Two Diseases.
Immune Evasion in Acute Myeloid Leukemia: From Biology to Clinical Targeting
Advancing Leukemia Diagnostics: What to do in 2020?
Session 2: Controversies in AML: Part I
ELN Guidelines for Diagnosis and Prognostication of AML
Is 3+7 Still the Standard for Younger Patients with AML?
Incorporating Venetoclax in AML Therapy
Session 3: Controversies in AML: Part II
FLT3 Inhibitors in AML
Immunotherapy in AML
MRD in AML: What we Have Learnt so Far
Session 4: Controversies in CML
Modern Management of CML, from Front-Line to TFR
CML: a Long-Term Outlook
End of Day One
Session 5: Controversies in CLL – Toward a New Paradigm of Cure?
Genetics and Clonal Evolution in CLL
CLL Management in 2020: Switching and Sequencing
Management of CLL Patients in 2020: Beyond Efficacy
Session 6: Controversies in ALL
Front-Line Treatment for Adult ALL: Which Place for Novel Agents?
Resistant/Relapsed ALL: What we have Learned from Clinical Trials?
Ph+ ALL: Chemotherapy, TKIs or Transplant?
Session 7: New Drugs, New Strategies
Overcoming Environment-Mediated Drug Resistance in AML
Exploiting NK Cell Receptors for CAR-T Cell Theraphy of AML
Targeting Tp53 in MDS and AML
Session 8: Controversies in Transplantation
Allogeneic Stem Cell Transplantation for Acute Leukemias: Is There an Upper Age Limit?
Presentation of Best Abstract I
Presentation of Best Abstract II